Selecta Biosciences, Inc. Capital Expenditures

Capital Expenditures of SELB for past 10 years: annual, quarterly and twelve month trailing (TTM) including Capital Expenditures growth rates and interactive chart. Capital expenditures, commonly known as Capex, are funds used by a company to acquire, upgrade, and maintain physical or intangible assets such as property, buildings, an industrial plant, technology, software or equipment. Capex is often used to undertake new projects or investments by the firm. A company must invest over its lifetime into productive assets to maintain its competitiveness and ensure its survival.


Highlights and Quick Summary

  • Capital Expenditures for the quarter ending December 30, 2020 was $-166 Thousand (a -41.96% decrease compared to previous quarter)
  • Year-over-year quarterly Capital Expenditures increased by 22.96%
  • Annual Capital Expenditures for 2020 was $-741 Thousand (a -1088.0% decrease from previous year)
  • Annual Capital Expenditures for 2019 was $75 Thousand (a -109.55% decrease from previous year)
  • Annual Capital Expenditures for 2018 was $-785 Thousand (a 7.68% increase from previous year)
  • Twelve month Capital Expenditures ending December 30, 2020 was $-741 Thousand (a 26.88% increase compared to previous quarter)
  • Twelve month trailing Capital Expenditures increased by 440.88% year-over-year
Trailing Capital Expenditures for the last four month:
30 Dec '20 29 Sep '20 29 Jun '20 30 Mar '20
$-741 Thousand $-584 Thousand $-286 Thousand $-137 Thousand
Visit stockrow.com/SELB for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Capital Expenditures of Selecta Biosciences, Inc.

Most recent Capital Expendituresof SELB including historical data for past 10 years.

Interactive Chart of Capital Expenditures of Selecta Biosciences, Inc.

Selecta Biosciences, Inc. Capital Expenditures for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-0.17 $-0.29 $-0.15 $-0.14 $-0.74
2019 $-0.01 $0.01 $-0.01 $0.08 $0.08
2018 $-0.37 $0.01 $-0.23 $-0.19 $-0.79
2017 $-0.15 $-0.13 $-0.4 $-0.06 $-0.73
2016 $-0.11 $-0.28 $-0.06 $-0.14 $-0.58
2015 $-0.13 $-0.48 $-0.55 $-1.16
2014 $-0.22 $-0.23

Business Profile of Selecta Biosciences, Inc.

Sector: Healthcare
Industry: Biotechnology
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and IgA vasculitis. The company also engages in the development of gene therapy product candidates that are in preclinical development, including MMA-101, a product candidate for the treatment methylmalonic academia; SEL-313, a product candidate to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to indicate appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and other products for the treatment of pompe disease, duchenne muscular dystrophy, and limb-girdle muscular dystrophy. In addition, it develops a product candidate to treat primary biliary cholangitis. The company has license and collaboration agreements with Swedish Orphan Biovitrum; Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.